Rafael Holdings Reports Q4 Revenue Decline and GAAP EPS Loss
Rafael Holdings (RFL) has released its fourth-quarter financial results, reporting a GAAP earnings per share (EPS) of -$0.18. The company's revenue for the period was $0.24 million, representing a significant year-over-year decline of 31.4%. Alongside the financial results, the company discussed clinical progress regarding its Phase III TransportNPC study of Trappsol Cyclo, intended for the treatment of Niemann-Pick Disease Type C. The combination of declining revenue and ongoing clinical trial expenses highlights the high-risk nature of the company's current operational phase.
Tickers: $RFL
Topics: biotechnology clinical trial results earnings report revenue decline